Warby Parker Inc. WRBY R2KR3KPHARMA
Company Overview
Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses. It also provides accessories, such as cases, pouches, lenses kit with anti-fog spray, travel cases, lenses cloth, anti-fog lens spray, and sun clip-ons through its stores, website, and mobile apps. In addition, the company offers eye exams and vision tests, as well as optical services. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.
Why Investors Should Care
Revenue has grown at a 18.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $871.90M (+13.0% YoY); net profit $1.64M.
- Trailing 12 Months Year-on-year growth — revenue +8.3%, earnings -9.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 18.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 18.67% |
| 1 Year: | 8.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -9.60% |
Stock Price Performance
| 1 Year: | -9.18% |
| 6 Months: | -1.89% |
| 3 Months: | +7.17% |
| 1 Month: | -9.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 18.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WRBY Warby Parker Inc. R2KR3KPHARMA | 24.35 | - | $2.62B | 0.00% | -0.93% | 0.37% | 18.67% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 104.09M | 138.97M | 131.56M | 137.37M | 153.22M | 149.62M | 148.78M | 171.97M | 166.09M | 169.85M | 200.00M | 188.22M | 192.45M | - | 223.78M | 214.47M | 221.68M | 211.97M | 242.45M | 235.51M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 97.80M | 100.87M | 101.73M | 100.92M | 111.41M | - |
| Gross Profit | - | - | 63.98M | 83.78M | 78.05M | 79.66M | 89.65M | 86.35M | 84.42M | 94.79M | 90.64M | 92.73M | 113.46M | 105.38M | 104.87M | - | 125.98M | 113.61M | 119.94M | 111.04M | 131.04M | 136.46M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 123.51M | 118.13M | 116.38M | 117.89M | 129.37M | - |
| Operating Income | - | - | -41.34M | 3.02M | -8.81M | -91.98M | -33.74M | -32.08M | -23.67M | -12.43M | -18.23M | -19.77M | -5.13M | -8.96M | -6.61M | - | 2.47M | -4.53M | 3.57M | -6.85M | 1.67M | 3.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.63M | 7.96M | 16.10M | 6.25M | 15.44M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.93M | -2.54M | 5.75M | -5.09M | 4.00M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.45M | -789.00K | -125.00K | 862.00K | 821.00K | - |
| Net Income | 2.78M | -12.79M | -41.61M | 3.01M | -10.31M | -91.07M | -34.13M | -32.17M | -10.81M | -10.81M | -15.93M | -17.41M | -2.68M | -6.76M | -4.07M | - | 3.47M | -1.75M | 5.87M | -5.95M | 3.18M | 4.64M |
| Diluted EPS | - | - | -0.78 | -0.03 | -0.35 | -1.45 | -0.30 | -0.28 | -0.21 | -0.09 | -0.14 | -0.15 | -0.02 | -0.06 | -0.03 | - | 0.03 | -0.01 | 0.05 | -0.05 | 0.03 | 0.04 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 370.46M | 393.72M | - | 598.11M | 669.76M | 771.32M | 871.90M |
| Cost of Revenue | - | - | - | 257.05M | 304.54M | 344.48M | 401.33M |
| Gross Profit | 223.11M | 231.94M | - | 341.06M | 365.22M | 426.83M | 470.58M |
| Operating Expenses | - | - | - | 452.26M | 437.22M | 456.95M | 475.92M |
| Operating Income | -1.66M | -55.63M | - | -111.20M | -72.00M | -30.11M | -5.34M |
| EBITDA | - | - | - | -79.34M | -33.44M | 15.75M | 44.94M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -109.90M | -62.76M | -19.52M | 3.04M |
| Tax Provision | - | - | - | 497.00K | 433.00K | 875.00K | 1.40M |
| Net Income | 0 | -55.92M | - | -110.39M | -63.20M | -20.39M | 1.64M |
| Diluted EPS | -1.10 | -1.05 | - | -0.96 | -0.54 | -0.17 | 0.01 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 444.75M | - | 568.71M | 580.31M | 676.49M | 720.92M |
| Current Assets | - | - | - | - | 294.57M | 298.62M | 326.05M | 352.44M |
| Cash & Equivalents | - | - | 314.08M | - | 208.59M | 216.89M | 254.16M | 286.36M |
| Inventory | - | - | - | - | 68.85M | 62.23M | 52.34M | 44.51M |
| Receivables | - | - | - | - | 1.44M | 1.78M | 1.95M | 3.29M |
| Total Liabilities | - | - | 136.34M | - | 282.06M | 278.52M | 336.42M | 353.19M |
| Current Liabilities | - | - | 105.33M | - | 129.56M | 127.09M | 130.35M | 150.13M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 173.38M | 174.46M | 225.35M | 233.15M |
| Total Equity | -133.59M | -189.45M | -198.10M | - | 286.65M | 301.79M | 340.07M | 367.73M |
| Shares Outstanding | - | - | - | - | 115.34M | 118.16M | 120.85M | 122.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 21.39M | 32.76M | - | 10.37M | 60.99M | 98.74M | 110.78M |
| Investing Cash Flow | -32.63M | -20.07M | - | -60.18M | -54.67M | -66.03M | -67.05M |
| Financing Cash Flow | -83.36M | 245.94M | - | 3.29M | 2.87M | 4.96M | -12.00M |
| Capital Expenditure | -32.63M | -20.07M | - | -60.18M | -53.67M | -64.03M | -67.05M |
| Free Cash Flow | -11.24M | 12.69M | - | -49.81M | 7.32M | 34.71M | 43.74M |
| Net Change in Cash | - | - | - | -46.52M | 9.19M | 37.67M | 31.74M |
| Share Buybacks | 79.47M | 0 | 8.09M | 0 | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 60.2% | 58.9% | - | 57.0% | 54.5% | 55.3% | 54.0% |
| Operating Margin % | -0.4% | -14.1% | - | -18.6% | -10.7% | -3.9% | -0.6% |
| Net Margin % | 0.0% | -14.2% | - | -18.5% | -9.4% | -2.6% | 0.2% |
| ROE % | -0.0% | 28.2% | - | -38.5% | -20.9% | -6.0% | 0.4% |
| ROCE % | - | -16.4% | - | -25.3% | -15.9% | -5.5% | -0.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.39% | 15.58M | $389.44M |
| 2 | Blackrock Inc. | 14.14% | 15.31M | $382.74M |
| 3 | JPMORGAN CHASE & CO | 10.27% | 11.11M | $277.77M |
| 4 | Durable Capital Partners Lp | 5.91% | 6.40M | $159.91M |
| 5 | Vanguard Portfolio Management LLC | 5.53% | 5.98M | $149.58M |
| 6 | Vanguard Capital Management LLC | 4.15% | 4.49M | $112.18M |
| 7 | State Street Corporation | 3.87% | 4.18M | $104.62M |
| 8 | Vaughan Nelson Investment Management, L.P. | 2.87% | 3.11M | $77.68M |
| 9 | Geode Capital Management, LLC | 2.38% | 2.57M | $64.28M |
| 10 | Fuller & Thaler Asset Management Inc. | 2.21% | 2.40M | $59.93M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WRBY
Kohl's, Ollie's, and Warby Parker Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after Walmart’s results reinforced worries about a stretched U.S. consumer. According to CNBC, Walmart (NYSE: WMT) shares fell nearly 10% even after a revenue beat and a full-year outlook rai…
Warby Parker (WRBY): Buy, Sell, or Hold Post Q2 Earnings?
Warby Parker trades at $25.91 per share and has stayed right on track with the overall market, gaining 11.2% over the last six months. At the same time, the S&P 500 has returned 12.9%.
Warby Parker (WRBY) Q2 2026 Earnings Call Transcript
Revenue grew 9.8% to $235.5 million as retail expansion and eye exams accelerate.
Warby Parker Q2 Earnings Call Highlights
Warby Parker (NYSE:WRBY) reported second-quarter revenue of $235.5 million, up 9.8% from a year earlier, as retail sales growth, eye exam expansion and higher average order values helped offset continued softness in customer traffic and the…
Warby Parker (WRBY) Unveils First Intelligent Eyewear Collection In Smart Wearables Push
Warby Parker (NYSE:WRBY) announced the launch of its first Intelligent Eyewear collection in collaboration with Google Gemini and Samsung. The collection introduces smart eyewear features that integrate with Google Gemini and Samsung techno…
Here's What Key Metrics Tell Us About Warby Parker (WRBY) Q2 Earnings
The headline numbers for Warby Parker (WRBY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.…
WRBY — Frequently Asked Questions
What is the current share price of Warby Parker Inc. (WRBY)?
As of 2026-09-07 16:24 PDT, Warby Parker Inc. (WRBY) trades at $24.35 on NYSE. Its 52-week range is $16.49 to $30.34.
What is the market capitalisation of WRBY?
Warby Parker Inc. (WRBY) has a market capitalisation of $2.62B on NYSE.
What is the return on equity (ROE) of WRBY?
WRBY has a return on equity (ROE) of 0.37%. Its return on capital employed (ROCE) is -0.93%.
Is WRBY a good stock to buy?
This page provides a data-driven analysis of Warby Parker Inc. (WRBY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.